Health officials revealed that in May 2026, 46 drug samples tested by Central Drugs Laboratories and 113 by State Drugs Testing Laboratories were found to be of substandard quality. Additionally, one spurious drug, manufactured by an unauthorized entity using another company's brand, was identified in Assam and is under investigation. These findings highlight ongoing efforts to ensure drug safety and remove substandard products from circulation.